Valuation concerns are rising after big share-price runs
This theme has appeared in 1 daily market analyses, first identified on Jun 29, 2026, most recently on Jun 29, 2026.
Every Mention of This Trend
Jun 29, 2026
When a stock has already had a very strong run, investors start asking whether the price has outrun the business fundamentals. That is especially true in healthcare and tech names with high expectations.
Supporting data: Guardant Health had a 193% one-year gain, a current price of $149, and a DCF-based discount of only 6.2% to intrinsic value, while its P/S ratio of 18.32x was far above the industry average and Simply Wall St’s Fair Ratio of 7.86x. Apple also fell 6.15% after price hikes sparked backlash.